What exactly changed in the Raymond James note for CCAP?

Raymond James on Feb 26, 2026 maintained an Outperform rating for CCAP and lowered its price target to $14. The CCAP analyst rating keeps a positive stance but reduces expected upside.

How should investors interpret the maintained Outperform in this CCAP analyst rating?

A maintained Outperform means the analyst expects CCAP to outperform peers. The lower price target narrows potential gains, so investors should check dividend coverage and NAV before acting.

Does the Raymond James action affect CCAP’s dividend or NAV outlook?

The note reflects valuation changes, not a direct dividend call. Review Crescent’s Q4 2025 earnings and strategic review for dividend and NAV details to pair with the CCAP analyst rating.

Where can I read the analyst note and the company earnings call?

The Raymond James note summary was posted on StreetInsider and the company’s Q4 2025 earnings transcript is on Seeking Alpha. Both give context to the CCAP analyst rating [StreetInsider source](https://www.streetinsider.com/Analyst+Comments/Crescent+BDC+%28CCAP%29+PT+Lowered+to+%2414+at+Raymond+Jane

Analyst Ratings

Raymond James Maintains Outperform on CCAP, Lowers PT to $14 Feb 2026

ByHuzaifa Zahoor February 28, 2026February 28, 2026

Raymond James on February 26, 2026 maintained an Outperform rating on Crescent Capital BDC, Inc. (CCAP) while cutting its price target to $14. This CCAP analyst rating keeps a positive tilt for the stock but signals lower near-term upside. The note, reported by StreetInsider, showed no immediate price move at release and listed price change as 0.0% ($0.0). We review the rating action, the new $14 target, and what it means for investors given CCAP’s current market cap of $468,510,304.